ESG risk score 27.07
Environmental score -
Social score -
Governance score -
ESG risk category Medium
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
Formycon AG
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol FYB:xetr
Currency EUR
Deutsche Börse (XETRA)
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Ready to start investing?
Trade stocks with a regulated broker present in Singapore since 2006.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -21.48%
1 year -26.64%
3 years -71.33%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -3.66
Volatility (30 days) 74.73%
Data provided by
Analyst consensus
Average rating Buy
Rating Analysts
Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Target price 38.75
Implied return 92.79%
Last updated 13-May-2026
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About Formycon AG
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
Sector Healthcare
Industry -
Market cap 0.364945385bn
Data provided by /
/ Frequently asked questions
You need to open and fund a Saxo account to buy Formycon AG stock. Once the account is approved, you can login to the platform (SaxoInvestor or SaxoTrader), search for Formycon AG (by name) or ‘FYB:xetr’ (by ticker), choose the number of shares you wish to buy, and place your order.
The ticker symbol for Formycon AG is FYB:xetr. You can use this code to find the stock in our platforms and track its price and performance.
Formycon AG has its primary listing on Deutsche Börse (XETRA). You can trade Formycon AG with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Formycon AG is available to trade on SaxoInvestor and SaxoTrader. You can buy Formycon AG stock directly and include it as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Formycon AG or others.